APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease

Journal of the American Society of Nephrology

Volumn 23, Issue 2, 2012, Pages 343-350

  Fine, Derek M ^a   Wasser, Walter G ^b   Estrella, Michelle M ^a   Atta, Mohamed G ^a   Kuperman, Michael ^a   Shemer, Revital ^c   Rajasekaran, Arun ^d   Tzur, Shay ^d   Racusen, Lorraine C ^a   Skorecki, Karl ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d KASTURBA MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; DISEASE COURSE; FEMALE; FOCAL GLOMERULOSCLEROSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE COMPLEX NEPHRITIS; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; SURVIVAL;

EID: 84856840591     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011060562     Document Type: Article

References (43)

1. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG: Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121: 651-658, 2010
2. Estrella MM, Parekh RS, Abraham A, Astor BC, Szczech LA, Anastos K, Dehovitz JA, Merenstein DJ, Pearce CL, Tien PC, Cohen MH,Gange SJ: The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 55: 217-220, 2010
3. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG: Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 24: 387-394, 2010
4. Naicker S, Fabian J: Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrol 74[Suppl 1]: S51-S56, 2010
5. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, Szczech LA, Grunfeld C, Shlipak MG: Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 56: 872-882, 2010
6. Bruggeman LA, RossMD, Tanji N, Cara A, Dikman S, Gordon RE, Burns GC, D'Agati VD, Winston JA, Klotman ME, Klotman PE: Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 11: 2079-2087, 2000
7. Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, Ross MD, Gusella GL, Benson G, D'Agati VD, Hahn BH, Klotman ME, Klotman PE: Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 8: 522-526, 2002 (Pubitemid 34546757)
8. Papeta N, Chan KT, Prakash S, Martino J, Kiryluk K, Ballard D, Bruggeman LA, Frankel R, Zheng Z, Klotman PE, Zhao H, D'Agati VD, Lifton RP, Gharavi AG: Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest 119: 1178-1188, 2009
9. Papeta N, Sterken R, Kiryluk K, Kalyesubula R, Gharavi AG: The molecular pathogenesis of HIV-1 associated nephropathy: Recent advances. J Mol Med (Berl) 89: 429-436, 2011
10. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, Klotman PE, D'Agati VD: The spectrumof kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 75: 428-434, 2009
11. Freedman BI, Soucie JM, Stone SM, Pegram S: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 34: 254-258, 1999 (Pubitemid 29362089)
12. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS Family Investigation of Nephropathy and Diabetes Research Group:MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185-1192, 2008
13. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175-1184, 2008
14. Shlush LI, Bercovici S, Wasser WG, Yudkovsky G, Templeton A, Geiger D, Skorecki K: Admixturemapping of end stage kidney disease genetic susceptibility using estimated mutual information ancestry informative markers. BMC Med Genomics 3: 47, 2010
15. Kopp JB, Winkler CA, Nelson GW: MYH9 genetic variants associated with glomerular disease: What is the role for genetic testing? Semin Nephrol 30: 409-417, 2010
16. Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K: The population genetics of chronic kidney disease: Insights from the MYH9-APOL1 locus. Nat Rev Nephrol 7: 313-326, 2011
17. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345-350, 2010
18. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845, 2010
19. Behar DM, Shlush LI, Maor C, Lorber M, Skorecki K: Absence of HIV-associated nephropathy in Ethiopians. Am J Kidney Dis 47: 88-94, 2006 (Pubitemid 41828270)
20. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21: 1422-1426, 2010
21. Berliner AR, Fine DM, Lucas GM, Rahman MH, Racusen LC, Scheel PJ, Atta MG: Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 28: 478-486, 2008 (Pubitemid 351501614)
22. Flateau C, Lescure FX, Plaisier E, Callard P, Pacanowski J, Girard PM, Ronco P, Pialoux G: Glomerular lesions in HIV-1-infected patients: Evolution from1996 to 2007, on 88 consecutive renal biopsies [abstract WEAB0302]. Presented at the International AIDS Conference, Vienna, Austria, July 21, 2010. Available at: http://pag.aids2010.org/Abstracts. aspx?SID=202&AID=15128. Accessed May 20, 2011
23. Tabatabai S, Sperati CJ, Atta MG, Janjua K, Roxbury C, Lucas GM, Fine DM: Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: Possible role of hepatitis C and HIV co-infection. Clin J Am Soc Nephrol 4: 1766-1773, 2009
24. Shegokar VR, Powar RM, Joshi PP, Bhargava A, Dani VS, Katti R, Zare VR, Khanande VD, Jannin J, Truc P: Short report: Human trypanosomiasis caused by Trypanosoma evansi in a village in India: Preliminary serologic survey of the local population. Am J Trop Med Hyg 75: 869-870, 2006 (Pubitemid 351627532)
25. Olsen S, Mogensen CE: How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 39: 1638-1645, 1996 (Pubitemid 26397381)
26. Samaras K: Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 50: 499-505, 2009
27. Duchateau PN, Pullinger CR, ChoMH, Eng C, Kane JP: Apolipoprotein L gene family: Tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res 42: 620-630, 2001 (Pubitemid 32367005)
28. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, Malloy MJ, Kane JP: Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272: 25576-25582, 1997 (Pubitemid 27438869)
29. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA: Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 283: 21540-21549, 2008
30. Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ: The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 79: 539-546, 2002 (Pubitemid 34274295)
31. Horrevoets AJ, Fontijn RD, van Zonneveld AJ, de Vries CJ, ten Cate JW, Pannekoek H: Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood 93: 3418-3431, 1999 (Pubitemid 29220909)
32. Page NM, Butlin DJ, Lomthaisong K, Lowry PJ: The human apolipoprotein L gene cluster: Identification, classification, and sites of distribution. Genomics 74: 71-78, 2001 (Pubitemid 32500267)
33. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI: The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11: 1025-1030, 2011
34. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F,Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, BurkeG, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011
35. Zhaorigetu S,Wan G, Kaini R, Jiang Z, Hu CA: ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 4: 1079-1082, 2008
36. Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK: Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 29: 256-269, 2005 (Pubitemid 40320926)
37. Smith EE, Malik HS: The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res 19: 850-858, 2009
38. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275, 2003 (Pubitemid 37329791)
39. Kopp J: Apolipoprotein L1 and non-musclemyosin IIA and their roles in FSGS. Paper presented at the World Congress of Nephrology, Vancouver, Canada, April 9, 2011
40. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA Jr, Germain MJ: Changing incidence of glomerular diseases in adults. Am J Kidney Dis 35: 878-883, 2000 (Pubitemid 30238200)
41. HaasM, Spargo BH, Coventry S: Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: A 20-year renal biopsy study. Am J Kidney Dis 26: 740-750, 1995
42. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44: 815-825, 2004 (Pubitemid 39445913)
43. D'Agati V: Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 23: 117-134, 2003